細菌性前立腺炎に対するcefclidinの臨床的検討

Abstract

CFCLのPFへの濃度移行を測定し, 臨床的には細菌性前立腺炎の治療に用いて以下の成績をえた.1) PFへの濃度移行は, 1 g, i.v.後1時間で平均0.84±0.72 μg/mlで対血清比は2.24%であった.2)細菌性前立腺炎に対してCFCLを1日1 g～2 gを平均6.5日投与した.急性には7例中7例が有効以上で100%の有効率を, 慢性には4例中1例で25%の有効率をえた.3)副作用では1例に一過期の発疹を認めた.臨検値の異常は, 全例に認めなかった

Cefclidin (CFCL), a new injectable cephem antibiotic, was used in the treatment of bacterial prostatitis. Concentration in prostatic fluid (PF): One hour after the i.v. administration of 1 g of CFCL the concentration of PF was 0.84 +/- 0.72 micrograms/ml (n = 4), the ratio of PF/serum being 2.24%. CFCL was administered at a dose of 1-2 g a day for 6.5 days on average. In acute bacterial prostatitis, the efficacy was evaluated as excellent or moderate in all 7 cases (100%), but in chronic cases, the effectiveness rate was as low as one out of 4 cases (25%). In safety profile, transient skin eruption was seen in one patient, but did not require further treatment. Besides this case, no side reactions or abnormal clinical values were encountered. In conclusion, CFCL was evaluated to be very useful in the treatment of acute bacterial prostatitis, caused by gram negative rods.